TN2011000187A1 - Organic compounds - Google Patents
Organic compoundsInfo
- Publication number
- TN2011000187A1 TN2011000187A1 TN2011000187A TN2011000187A TN2011000187A1 TN 2011000187 A1 TN2011000187 A1 TN 2011000187A1 TN 2011000187 A TN2011000187 A TN 2011000187A TN 2011000187 A TN2011000187 A TN 2011000187A TN 2011000187 A1 TN2011000187 A1 TN 2011000187A1
- Authority
- TN
- Tunisia
- Prior art keywords
- organic compounds
- alky
- polymorphs
- hydrates
- diol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168862 | 2008-11-11 | ||
| PCT/EP2009/064889 WO2010055027A2 (fr) | 2008-11-11 | 2009-11-10 | Composés organiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000187A1 true TN2011000187A1 (en) | 2012-12-17 |
Family
ID=42062355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000187A TN2011000187A1 (en) | 2008-11-11 | 2011-04-19 | Organic compounds |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8680146B2 (fr) |
| EP (1) | EP2358660A2 (fr) |
| JP (2) | JP2012508215A (fr) |
| KR (1) | KR20110086142A (fr) |
| CN (2) | CN102256933A (fr) |
| AU (1) | AU2009315735B2 (fr) |
| BR (1) | BRPI0921533A2 (fr) |
| CA (1) | CA2741974A1 (fr) |
| CL (1) | CL2011001041A1 (fr) |
| CO (1) | CO6382154A2 (fr) |
| EC (1) | ECSP11011121A (fr) |
| IL (1) | IL212073A0 (fr) |
| MA (1) | MA32877B1 (fr) |
| MX (1) | MX2011004924A (fr) |
| NZ (1) | NZ591999A (fr) |
| PE (1) | PE20120012A1 (fr) |
| RU (1) | RU2543621C2 (fr) |
| TN (1) | TN2011000187A1 (fr) |
| WO (1) | WO2010055027A2 (fr) |
| ZA (1) | ZA201102272B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101321742B (zh) | 2005-05-26 | 2012-08-29 | 神经元系统公司 | 用于治疗视网膜疾病的组合物和方法 |
| US8680146B2 (en) * | 2008-11-11 | 2014-03-25 | Novartis Ag | Organic compounds |
| EP2896609B1 (fr) * | 2009-07-24 | 2018-06-27 | ratiopharm GmbH | Citrate de fingolimod crystallin pour le traitement de la sclérose en plaques récurrente-rémittente |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| WO2012056458A2 (fr) | 2010-10-28 | 2012-05-03 | Mapi Pharma Ltd. | Composés intermédiaires et procédé de préparation de fingolimod |
| WO2012071524A1 (fr) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Sels d'arylsulfonates de fingolimod et leurs procédés de préparation |
| EP2505589A1 (fr) | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| AU2014224237B2 (en) | 2013-03-05 | 2017-07-20 | Biocon Limited | A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof |
| US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| CN105611917A (zh) | 2013-10-11 | 2016-05-25 | 帝国制药美国公司 | 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法 |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| CA2974375A1 (fr) * | 2015-01-20 | 2016-07-28 | Handa Pharmaceuticals, Llc | Forme galenique solide stable de fingolimod |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| JP7116490B2 (ja) | 2016-05-09 | 2022-08-10 | アルデイラ セラピューティクス, インコーポレイテッド | 眼の炎症性障害および疾患の組合せ処置 |
| RU2732572C2 (ru) | 2016-05-31 | 2020-09-21 | Тайхо Фармасьютикал Ко., Лтд. | Сульфонамидное соединение или его соль |
| RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス, インコーポレイテッド | 炎症性障害の処置 |
| BR112020010148A2 (pt) | 2017-11-29 | 2020-10-13 | Taiho Pharmaceutical Co., Ltd. | compostos de sulfonamida e uso dos mesmos |
| AU2019293260A1 (en) * | 2018-06-29 | 2021-01-07 | Forma Therapeutics, Inc. | Salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)(cyclopropyl)methanone and solid forms thereof |
| CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| CA3156298A1 (fr) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1 |
| JP2023526016A (ja) | 2020-05-13 | 2023-06-20 | アルデイラ セラピューティクス, インコーポレイテッド | 医薬製剤およびその使用 |
| JP2024521882A (ja) * | 2021-05-31 | 2024-06-04 | 上海雲晟研新生物科技有限公司 | フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用 |
| EP4212156A1 (fr) | 2022-01-13 | 2023-07-19 | Abivax | Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627406B1 (fr) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose 2-amino-1,3-propanediol et immunosuppresseur |
| ECSP951461A (es) | 1995-06-07 | 1998-04-07 | SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B) | |
| ECSP972265A (es) | 1997-09-23 | 1998-11-30 | Dihidrato de d-olanzapina | |
| FR2785607B1 (fr) | 1998-11-09 | 2001-02-09 | Rhodia Chimie Sa | Procede de preparation de tris(ether-amine) |
| PT1129066E (pt) * | 1998-11-11 | 2005-05-31 | Taito Co | Producao de 2-amino-2-[2-(4-c2-20-alquil-fenil)etil]propano-1,3-diois |
| JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| CN1524002A (zh) * | 2001-06-08 | 2004-08-25 | ��˹��ŵ�� | 治疗或预防产胰岛素细胞的移植排斥反应 |
| PT1505959E (pt) * | 2002-05-16 | 2009-02-05 | Novartis Ag | Utilização de agentes de ligação do receptor edg em cancro |
| GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| US20060275357A1 (en) | 2003-04-08 | 2006-12-07 | Tomoyuki Oomura | Organic compounds |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| US20080221200A1 (en) * | 2005-09-30 | 2008-09-11 | Malcolm Allison | Combination of Organic Compounds |
| EP2046315B1 (fr) * | 2006-06-02 | 2013-04-10 | The Ohio State University Research Foundation | Agents thérapeutiques destinés au traitement du lymphome a cellules du manteau |
| US7985586B2 (en) * | 2008-02-04 | 2011-07-26 | Georgia Health Sciences University | Oligodendrocyte precursor cell composition and methods of use |
| US8680146B2 (en) * | 2008-11-11 | 2014-03-25 | Novartis Ag | Organic compounds |
-
2009
- 2009-11-10 US US13/128,832 patent/US8680146B2/en not_active Expired - Fee Related
- 2009-11-10 CN CN2009801448205A patent/CN102256933A/zh active Pending
- 2009-11-10 BR BRPI0921533A patent/BRPI0921533A2/pt not_active IP Right Cessation
- 2009-11-10 WO PCT/EP2009/064889 patent/WO2010055027A2/fr not_active Ceased
- 2009-11-10 KR KR1020117013304A patent/KR20110086142A/ko not_active Ceased
- 2009-11-10 RU RU2011123365/04A patent/RU2543621C2/ru not_active IP Right Cessation
- 2009-11-10 AU AU2009315735A patent/AU2009315735B2/en not_active Ceased
- 2009-11-10 EP EP09752168A patent/EP2358660A2/fr not_active Withdrawn
- 2009-11-10 CA CA2741974A patent/CA2741974A1/fr not_active Abandoned
- 2009-11-10 CN CN201510547567.5A patent/CN105198760A/zh active Pending
- 2009-11-10 NZ NZ591999A patent/NZ591999A/xx not_active IP Right Cessation
- 2009-11-10 JP JP2011535129A patent/JP2012508215A/ja not_active Withdrawn
- 2009-11-10 MX MX2011004924A patent/MX2011004924A/es active IP Right Grant
- 2009-11-10 PE PE2011000987A patent/PE20120012A1/es not_active Application Discontinuation
-
2011
- 2011-03-28 ZA ZA2011/02272A patent/ZA201102272B/en unknown
- 2011-03-31 IL IL212073A patent/IL212073A0/en unknown
- 2011-04-19 TN TN2011000187A patent/TN2011000187A1/fr unknown
- 2011-05-10 CL CL2011001041A patent/CL2011001041A1/es unknown
- 2011-05-12 CO CO11058592A patent/CO6382154A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33910A patent/MA32877B1/fr unknown
- 2011-06-10 EC EC2011011121A patent/ECSP11011121A/es unknown
-
2014
- 2014-02-13 US US14/179,807 patent/US20140235722A1/en not_active Abandoned
-
2015
- 2015-04-24 JP JP2015089480A patent/JP2015178503A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US8680146B2 (en) | 2014-03-25 |
| IL212073A0 (en) | 2011-06-30 |
| US20110218248A1 (en) | 2011-09-08 |
| NZ591999A (en) | 2013-06-28 |
| EP2358660A2 (fr) | 2011-08-24 |
| PE20120012A1 (es) | 2012-02-02 |
| MX2011004924A (es) | 2011-05-30 |
| CL2011001041A1 (es) | 2011-10-07 |
| CO6382154A2 (es) | 2012-02-15 |
| WO2010055027A3 (fr) | 2010-08-19 |
| AU2009315735B2 (en) | 2013-01-10 |
| MA32877B1 (fr) | 2011-12-01 |
| WO2010055027A2 (fr) | 2010-05-20 |
| AU2009315735A1 (en) | 2010-05-20 |
| RU2011123365A (ru) | 2012-12-20 |
| RU2543621C2 (ru) | 2015-03-10 |
| ECSP11011121A (es) | 2011-07-29 |
| JP2012508215A (ja) | 2012-04-05 |
| CN105198760A (zh) | 2015-12-30 |
| ZA201102272B (en) | 2011-12-28 |
| CN102256933A (zh) | 2011-11-23 |
| CA2741974A1 (fr) | 2010-05-20 |
| JP2015178503A (ja) | 2015-10-08 |
| BRPI0921533A2 (pt) | 2016-01-12 |
| US20140235722A1 (en) | 2014-08-21 |
| KR20110086142A (ko) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000187A1 (en) | Organic compounds | |
| MY153915A (en) | Organic compounds | |
| MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
| IN2012DN00624A (fr) | ||
| MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| EP2297140A4 (fr) | Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation | |
| UA105390C2 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
| AP2010005480A0 (en) | Small molecule inhibitors for the treatment or prevention of denque virus infection. | |
| MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
| JO2892B1 (en) | CYP inhibitors 17 | |
| WO2010055028A3 (fr) | Composés organiques | |
| WO2007115821A3 (fr) | Composés organiques | |
| MX2013004570A (es) | Mezclas fungicidas de penflufen. | |
| MX2012004780A (es) | Inhibidores de akt. | |
| LT2252300T (lt) | 2,4-pirimidindiaminų panaudojimas aterosklerozės gydymui | |
| ZA200908612B (en) | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase | |
| CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MY150600A (en) | Use of opioid antagonists for treating urinary retention | |
| EP2499120A4 (fr) | Nouveaux composés de 1,3-oxazolidine et utilisation de ces derniers comme inhibiteurs de la rénine | |
| WO2010074936A3 (fr) | Enzastaurine dans le traitement du cancer | |
| CL2007000773A1 (es) | Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd. | |
| GB201020397D0 (en) | Compounds | |
| MX2010001303A (es) | Compuestos terapeuticos. |